Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2

Yasuo Imai, Etsuko Ishikawa, Sakiyo Asada, Yoshikazu Sugimoto

研究成果: Article

129 引用 (Scopus)

抄録

Breast cancer resistance protein (BCRP)/ABCG2 mediates concurrent resistance to chemotherapeutic agents, such as 7-ethyl-10-hydroxycamptothecin (SN-38), mitoxantrone, and topotecan, by pumping them out of cells. We previously reported that BCRP transports sulfated estrogens. In the present study, we show that at physiologic levels, estrogens markedly decrease endogenous BCRP expression in the estrogen-responsive and estrogen receptor α (ERα)-positive human breast cancer MCF-7 cells, but not in estrogen-nonresponsive human cancer cells. 17 β-Estradiol (E2) also significantly reduces exogenous BCRP expression, driven by a constitutive promoter, in BCRP-transduced estrogen-responsive and ERα-positive MCF-7 (MCF-7/BCRP) and T-47D cells, but not in BCRP-transduced estrogen-nonresponsive MDA-MB-231 and SKOV-3 cells. E2 potentiates the cytotoxicity of SN-38, but not vincristine, in MCF-7/BCRP cells significantly, and increases cellular topotecan uptake in MCF-7 and MCF-7/ BCRP cells. Antiestrogen tamoxifen partially reverses E2-mediated BCRP down-regulation in MCF-7 and MCF-7/ BCRP cells and treatment of MCF-7/BCRP cells with an ERα small interfering RNA abolished E2-mediated BCRP down-regulation, suggesting that interaction of E2 and ERα is necessary for BCRP down-regulation. E2 does not affect endogenous BCRP mRNA levels in MCF-7 cells or exogenous BCRP mRNA levels in MCF-7/BCRP cells. The results from pulse-chase labeling experiments with MCF-7/BCRP cells suggest that decreased protein biosynthesis and maturation, but not alterations in protein turnover, might underlie E2-mediated BCRP down-regulation. These data indicate that estrogen down-regulates BCRP expression by novel posttranscriptional mechanisms. This is the first report of small molecules that can affect BCRP protein expression in cells and may therefore assist in establishing new strategies for regulating BCRP expression.

元の言語English
ページ(範囲)596-604
ページ数9
ジャーナルCancer Research
65
発行部数2
出版物ステータスPublished - 2005 1 15

Fingerprint

Estrogens
Down-Regulation
Breast Neoplasms
Proteins
irinotecan
Estrogen Receptors
ATP Binding Cassette Transporter, Sub-Family G, Member 2
MCF-7 Cells
Topotecan
Mitoxantrone
Messenger RNA
Estrogen Receptor Modulators
Protein Biosynthesis
Vincristine
Protein Transport
Tamoxifen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

これを引用

Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. / Imai, Yasuo; Ishikawa, Etsuko; Asada, Sakiyo; Sugimoto, Yoshikazu.

:: Cancer Research, 巻 65, 番号 2, 15.01.2005, p. 596-604.

研究成果: Article

Imai, Yasuo ; Ishikawa, Etsuko ; Asada, Sakiyo ; Sugimoto, Yoshikazu. / Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. :: Cancer Research. 2005 ; 巻 65, 番号 2. pp. 596-604.
@article{35cfd2087cb9494c9f8bd353ccb0224d,
title = "Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2",
abstract = "Breast cancer resistance protein (BCRP)/ABCG2 mediates concurrent resistance to chemotherapeutic agents, such as 7-ethyl-10-hydroxycamptothecin (SN-38), mitoxantrone, and topotecan, by pumping them out of cells. We previously reported that BCRP transports sulfated estrogens. In the present study, we show that at physiologic levels, estrogens markedly decrease endogenous BCRP expression in the estrogen-responsive and estrogen receptor α (ERα)-positive human breast cancer MCF-7 cells, but not in estrogen-nonresponsive human cancer cells. 17 β-Estradiol (E2) also significantly reduces exogenous BCRP expression, driven by a constitutive promoter, in BCRP-transduced estrogen-responsive and ERα-positive MCF-7 (MCF-7/BCRP) and T-47D cells, but not in BCRP-transduced estrogen-nonresponsive MDA-MB-231 and SKOV-3 cells. E2 potentiates the cytotoxicity of SN-38, but not vincristine, in MCF-7/BCRP cells significantly, and increases cellular topotecan uptake in MCF-7 and MCF-7/ BCRP cells. Antiestrogen tamoxifen partially reverses E2-mediated BCRP down-regulation in MCF-7 and MCF-7/ BCRP cells and treatment of MCF-7/BCRP cells with an ERα small interfering RNA abolished E2-mediated BCRP down-regulation, suggesting that interaction of E2 and ERα is necessary for BCRP down-regulation. E2 does not affect endogenous BCRP mRNA levels in MCF-7 cells or exogenous BCRP mRNA levels in MCF-7/BCRP cells. The results from pulse-chase labeling experiments with MCF-7/BCRP cells suggest that decreased protein biosynthesis and maturation, but not alterations in protein turnover, might underlie E2-mediated BCRP down-regulation. These data indicate that estrogen down-regulates BCRP expression by novel posttranscriptional mechanisms. This is the first report of small molecules that can affect BCRP protein expression in cells and may therefore assist in establishing new strategies for regulating BCRP expression.",
author = "Yasuo Imai and Etsuko Ishikawa and Sakiyo Asada and Yoshikazu Sugimoto",
year = "2005",
month = "1",
day = "15",
language = "English",
volume = "65",
pages = "596--604",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2

AU - Imai, Yasuo

AU - Ishikawa, Etsuko

AU - Asada, Sakiyo

AU - Sugimoto, Yoshikazu

PY - 2005/1/15

Y1 - 2005/1/15

N2 - Breast cancer resistance protein (BCRP)/ABCG2 mediates concurrent resistance to chemotherapeutic agents, such as 7-ethyl-10-hydroxycamptothecin (SN-38), mitoxantrone, and topotecan, by pumping them out of cells. We previously reported that BCRP transports sulfated estrogens. In the present study, we show that at physiologic levels, estrogens markedly decrease endogenous BCRP expression in the estrogen-responsive and estrogen receptor α (ERα)-positive human breast cancer MCF-7 cells, but not in estrogen-nonresponsive human cancer cells. 17 β-Estradiol (E2) also significantly reduces exogenous BCRP expression, driven by a constitutive promoter, in BCRP-transduced estrogen-responsive and ERα-positive MCF-7 (MCF-7/BCRP) and T-47D cells, but not in BCRP-transduced estrogen-nonresponsive MDA-MB-231 and SKOV-3 cells. E2 potentiates the cytotoxicity of SN-38, but not vincristine, in MCF-7/BCRP cells significantly, and increases cellular topotecan uptake in MCF-7 and MCF-7/ BCRP cells. Antiestrogen tamoxifen partially reverses E2-mediated BCRP down-regulation in MCF-7 and MCF-7/ BCRP cells and treatment of MCF-7/BCRP cells with an ERα small interfering RNA abolished E2-mediated BCRP down-regulation, suggesting that interaction of E2 and ERα is necessary for BCRP down-regulation. E2 does not affect endogenous BCRP mRNA levels in MCF-7 cells or exogenous BCRP mRNA levels in MCF-7/BCRP cells. The results from pulse-chase labeling experiments with MCF-7/BCRP cells suggest that decreased protein biosynthesis and maturation, but not alterations in protein turnover, might underlie E2-mediated BCRP down-regulation. These data indicate that estrogen down-regulates BCRP expression by novel posttranscriptional mechanisms. This is the first report of small molecules that can affect BCRP protein expression in cells and may therefore assist in establishing new strategies for regulating BCRP expression.

AB - Breast cancer resistance protein (BCRP)/ABCG2 mediates concurrent resistance to chemotherapeutic agents, such as 7-ethyl-10-hydroxycamptothecin (SN-38), mitoxantrone, and topotecan, by pumping them out of cells. We previously reported that BCRP transports sulfated estrogens. In the present study, we show that at physiologic levels, estrogens markedly decrease endogenous BCRP expression in the estrogen-responsive and estrogen receptor α (ERα)-positive human breast cancer MCF-7 cells, but not in estrogen-nonresponsive human cancer cells. 17 β-Estradiol (E2) also significantly reduces exogenous BCRP expression, driven by a constitutive promoter, in BCRP-transduced estrogen-responsive and ERα-positive MCF-7 (MCF-7/BCRP) and T-47D cells, but not in BCRP-transduced estrogen-nonresponsive MDA-MB-231 and SKOV-3 cells. E2 potentiates the cytotoxicity of SN-38, but not vincristine, in MCF-7/BCRP cells significantly, and increases cellular topotecan uptake in MCF-7 and MCF-7/ BCRP cells. Antiestrogen tamoxifen partially reverses E2-mediated BCRP down-regulation in MCF-7 and MCF-7/ BCRP cells and treatment of MCF-7/BCRP cells with an ERα small interfering RNA abolished E2-mediated BCRP down-regulation, suggesting that interaction of E2 and ERα is necessary for BCRP down-regulation. E2 does not affect endogenous BCRP mRNA levels in MCF-7 cells or exogenous BCRP mRNA levels in MCF-7/BCRP cells. The results from pulse-chase labeling experiments with MCF-7/BCRP cells suggest that decreased protein biosynthesis and maturation, but not alterations in protein turnover, might underlie E2-mediated BCRP down-regulation. These data indicate that estrogen down-regulates BCRP expression by novel posttranscriptional mechanisms. This is the first report of small molecules that can affect BCRP protein expression in cells and may therefore assist in establishing new strategies for regulating BCRP expression.

UR - http://www.scopus.com/inward/record.url?scp=12544251673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12544251673&partnerID=8YFLogxK

M3 - Article

C2 - 15695404

AN - SCOPUS:12544251673

VL - 65

SP - 596

EP - 604

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 2

ER -